TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03149107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine
Description: N-Acetylcysteine (2000 mg/d, 1000 mg in the morning/evening, oral intake). Will be applied continously over 26 weeks parallel to the psychological intervention (IPPI or PSM).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine
Description: N-Acetylcysteine (2000 mg/d, 1000 mg in the morning/evening, oral intake). Will be applied continously over 26 weeks parallel to the psychological intervention (IPPI or PSM).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Will be applied continously over 26 weeks (oral intake of capsules) parallel to the psychological intervention (IPPI or PSM).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Will be applied continously over 26 weeks (oral intake of capsules) parallel to the psychological intervention (IPPI or PSM).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IPPI (Integrated Preventive Psychological Intervention)
Description: IPPI (Integrated Preventive Psychological Intervention): 21 sessions, the first 20 sessions are scheduled weekly, the last session two weeks after session 20. Single blinded (statistician \& rater)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IPPI (Integrated Preventive Psychological Intervention)
Description: IPPI (Integrated Preventive Psychological Intervention): 21 sessions, the first 20 sessions are scheduled weekly, the last session two weeks after session 20. Single blinded (statistician \& rater)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PSM (Psychological stress management)
Description: PSM (Psychological stress management): 11 sessions; the first 10 sessions will be offered biweekly, the last one 2 weeks after session 10. Single blinded (statistician \& rater).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PSM (Psychological stress management)
Description: PSM (Psychological stress management): 11 sessions; the first 10 sessions will be offered biweekly, the last one 2 weeks after session 10. Single blinded (statistician \& rater).
Study: NCT01983527

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthrographic distention
Description: Arthrographic distention of the glenohumeral joint with injection of 5 ml contrast, 15 ml local anaesthetic (Prilocaine) and up to 15 ml saline.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthrographic distention
Description: Arthrographic distention of the glenohumeral joint with injection of 5 ml contrast, 15 ml local anaesthetic (Prilocaine) and up to 15 ml saline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intra-articular corticosteroid Depo Medrol
Description: Intra-articular injection of 1 ml (40 mg) Depo Medrol(Methylprednisolone Acetate Injectable Suspension)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intra-articular corticosteroid Depo Medrol
Description: Intra-articular injection of 1 ml (40 mg) Depo Medrol(Methylprednisolone Acetate Injectable Suspension)
Study: NCT01105429

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Oral Solution, Oral, 0mg, once daily, 1 day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Capsule, Oral, (TBD), once daily, 2 days
Study: NCT00380601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRA(Tocilizumab)
Description: 8mg/kg/4 weeks
Study: NCT00582842

Intervention type: BEHAVIORAL
Intervention: Interview
Description: The phone interview will consist of the following items from the follow up questionnaire; 14, 16, 20, 32, 33, 46, 47, 60, and 65. An additional component of this study would be dispensing the HRQOL tool to long-term survivors 10 years or greater after the completion of therapy. The long term QoL study will be a cross-sectional assessment measuring HRQOL in prostate cancer survivors, free of disease at least ten years post-treatment. Patients will complete a questionnaire by selfreport focusing on assessment of HRQOL.

Intervention type: BEHAVIORAL
Intervention: survey instruments using Web-Based Data Collection System (WBDC) survey content
Description: The content of the WBDC questionnaire will be similar to the paper form, no alteration in the wording, the order, or the formate of the items will be done. In addition, at the time of each outpatient clinic visit to MSKCC, these subjects will be able to login to WBDC using a computer located in the patient waiting-area, and enter their responses to the different items of the questionnaire if their clinic visit corresponds to any of the study time points 3, 6, 9, 12, 15, 18, 24, 36, and 48 following treatment). An additional component of this study would be dispensing the HRQOL tool to long-term survivors 10 years or greater after the completion of therapy. The long term QoL study will be a cross-sectional assessment measuring HRQOL in prostate cancer survivors, free of disease at least ten years post-treatment. Patients will complete a questionnaire by selfreport focusing on assessment of HRQOL.
Study: NCT03342547

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Duodenal biopsy
Description: Two duodenal biopsy samples will be collected from each participant

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Saliva
Description: Saliva (1-2 mL) will be collected from each participant for secretor status testing
Study: NCT02687984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBP-7000
Description: A single subcutaneous injection with doses of RBP-7000 containing 120 mg risperidone and either a low, high, or intermediate molecular weight PLGH polymer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBP-7000
Description: A single subcutaneous injection with doses of RBP-7000 containing 120 mg risperidone and either a low, high, or intermediate molecular weight PLGH polymer.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RBP-7000
Description: A single subcutaneous injection with doses of RBP-7000 containing 120 mg risperidone and either a low, high, or intermediate molecular weight PLGH polymer.
Study: NCT03419689

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumour tissue collection
Description: Tumour tissue will be taken from samples already removed from surgery or biopsy or by new tumour biopsies:~* At the time of diagnosis or progression~* Any surgical procedures for management of tumour related medical conditions~* At each subsequent relapse or disease progression

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sample collection
Description: Blood samples will be taken:~* At the time of first diagnosis~* About 1 week after starting any treatment~* At each radiological response assessment~* At each subsequent relapse or disease progression

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ascites Collection
Description: Ascites will be collected if paracentesis is required during any of the following time points:~* At the time of diagnosis or progression~* Any surgical procedures for management of tumour related medical conditions~* At each subsequent relapse or disease progression

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fluid Collection
Description: Additional fluid will be collected at any time a procedure for clinical management that involves the drainage of fluid (i.e. thoracentesis, or drainage of cystic lesion) is required.
Study: NCT03659929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amphetamine Sulfate
Description: active experimental AR19

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amphetamine Sulfate
Description: active experimental AR19

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study: NCT03333265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100mg Berberine hydrochloride
Description: patients take the Berberine hydrochloride 100mg tablet by mouth, 2 times a day with 6 months
Study: NCT04474314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMR-687
Description: Oral administration of once daily IMR-687

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration of once daily Placebo
Study: NCT03333265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 300mg Berberine hydrochloride
Description: patients take the Berberine hydrochloride 300mg tablet by mouth, 2 times a day with 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: patients take mmic Berberine hydrochloride tablet by mouth, 2 times a day with 6 months
Study: NCT02813941

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Current GRADE SoF table
Description: The current GRADE SoF table will be the common comparator for the other two SoF tables

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alternative GRADE SoF table
Description: The alternative GRADE SoF table format will be developed from a user-testing survey.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EPC SoF table
Description: For the EPC SoF table, the investigators will use one of their format which was recently published
Study: NCT01804972

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Verbal and written information
Description: Patients will receive verbal information supplied by the attending doctor and also written information in the form of patient information leaflets

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Verbal and electronic information
Description: Patients will receive verbal information by the attending doctor and also be provided with a web address to access electronic patient information.
Study: NCT03762694

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Electroacupuncture (EA) and Auricular Acupuncture (AA)
Study: NCT01911897

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MobiusHD
Description: Implant that is placed in the carotid sinus to control hypertension.
Study: NCT03333135

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulsed Electromagnetic Field therapy (PEMF)
Description: PEMF Therapy based on Biological Electromagnetic (BEM) microbial wave technology provides micro-magnetic emissions to the center of the palm (Laogong acupoint). While participating in the study, the subjects will undertake 2 sessions of therapy every day (1 session in the morning and evening). Each session will last for 16-min (8-min for left and 8-min for right hand).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulsed Electromagnetic Field therapy (PEMF)
Description: PEMF Therapy based on Biological Electromagnetic (BEM) microbial wave technology provides micro-magnetic emissions to the center of the palm (Laogong acupoint). While participating in the study, the subjects will undertake 2 sessions of therapy every day (1 session in the morning and evening). Each session will last for 16-min (8-min for left and 8-min for right hand).

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Pulsed Electromagnetic Field Sham therapy
Description: PEMF therapy will be administered however it will not produce micro-magnetic emissions. The therapy will be used on the center of the palm (Laogong acupoint) of each hand. While participating in the study, the subjects will undertake 2 sessions of therapy every day (1 session in the morning and evening). Each session will last for 16-min (8-min for left and 8-min for right hand).

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Pulsed Electromagnetic Field Sham therapy
Description: PEMF therapy will be administered however it will not produce micro-magnetic emissions. The therapy will be used on the center of the palm (Laogong acupoint) of each hand. While participating in the study, the subjects will undertake 2 sessions of therapy every day (1 session in the morning and evening). Each session will last for 16-min (8-min for left and 8-min for right hand).
Study: NCT00619060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Myristyl Nicotinate Cream
Description: Participants apply topical myristyl nicotinate to one forearm once daily for 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Myristyl Nicotinate Cream
Description: Participants apply topical myristyl nicotinate to one forearm once daily for 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants apply topical placebo to one forearm once daily for 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants apply topical placebo to one forearm once daily for 4 weeks.
Study: NCT02716545

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: balloon assisted enteroscopy
Description: Patients with recurrent bleeding (\>2 times for one year) will undergo balloon assisted enteroscopy and be treated with endoscopic therapy if necessary. Currently available endoscopic modalities are argon laser, bipolar electrocoagulation (BiCAP), band ligation, cryotherapy, radiofrequency ablation and argon plasma coagulation (APC). Among these options, APC is the most promising.
Study: NCT05304312

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kegel Exercises guidebook
Description: The Kegel exercises book is consisted of basic explanation about stress urinary incontinence and Kegel exercises, how to do Kegel exercises, table for them to write how many session they did in a day, and lastly their report progress (UDI-6, IIQ-7, periineometer, and 1-hour pad test) that we updated every four weeks
Study: NCT03544307

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Taekwondo training
Description: Exercise group
Study: NCT00436592

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuroFlo™ Catheter
Description: 45 minute Treatment
Study: NCT00903331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-064992 (macitentan)
Description: ACT-064992 (macitentan) tablet, 10 mg, once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo, once daily
Study: NCT03525132

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser Doppler Velocimetry + Optic Adaptative Camera
Description: Fluxometry measure while subject is sitting in front of the optic adaptative camera

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser Doppler Velocimetry + Optic Adaptative Camera
Description: Fluxometry measure while subject is sitting in front of the optic adaptative camera
Study: NCT04003493

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition and oral health intervention
Description: The interventions included individualised nutrition and oral health care.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition and oral health intervention
Description: The interventions included individualised nutrition and oral health care.
Study: NCT01340131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-828
Description: Drug: Telmisartan 40mg + S-Amlodipine 5mg(FDC) Tablet, Oral, Once Daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combination Therapy
Description: Drug: Telmisartan 40mg Tablet, Oral, Once Daily~Drug: S-amlodipine 5mg Tablet, Oral, Once Daily
Study: NCT03340974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC4419
Description: 90 mg Avasopasem (GC4419) per day daily (60 min IV infusion, prior to SBRT), concurrent with daily fractions of SBRT to assigned dose level

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC4419
Description: 90 mg Avasopasem (GC4419) per day daily (60 min IV infusion, prior to SBRT), concurrent with daily fractions of SBRT to assigned dose level

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo daily (60 min IV infusion, prior to SBRT), concurrent with daily fractions of SBRT to assigned dose level

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo daily (60 min IV infusion, prior to SBRT), concurrent with daily fractions of SBRT to assigned dose level

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiation Therapy (SBRT) 50 Gy
Description: Dose-finding will be done using the sequentially adaptive phase I-II Late onset Efficacy-Toxicity (LO-ET) trade-off-based design.

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Stereotactic Radiation Therapy (SBRT) 50 Gy
Description: Dose-finding will be done using the sequentially adaptive phase I-II Late onset Efficacy-Toxicity (LO-ET) trade-off-based design.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiation Therapy (SBRT) 55 Gy
Description: Dose-finding will be done using the sequentially adaptive phase I-II Late onset Efficacy-Toxicity (LO-ET) trade-off-based design.

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Stereotactic Radiation Therapy (SBRT) 55 Gy
Description: Dose-finding will be done using the sequentially adaptive phase I-II Late onset Efficacy-Toxicity (LO-ET) trade-off-based design.
Study: NCT03742505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: Single enteral cholecalciferol load at a dose of 10,000 IU/kg (maximum 400,000 IU)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single enteral placebo dose equivalent in volume to the appropriate weight-based dose of cholecalciferol
Study: NCT05593094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZN-A-1041 50mg BID
Description: twice a day (BID) via oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZN-A-1041 100mg BID
Description: twice a day (BID) via oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZN-A-1041 200mg BID
Description: twice a day (BID) via oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZN-A-1041 400mg BID
Description: twice a day (BID) via oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZN-A-1041 600mg BID
Description: twice a day (BID) via oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZN-A-1041 800mg BID
Description: twice a day (BID) via oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZN-A-1041 1000mg BID
Description: twice a day (BID) via oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase1b
Description: ZN-A-1041: twice a day (BID) via oral administration T-DM1: 3.6 mg/kg given as an intravenous infusion on the first day of each treatment cycle, once every 3 weeks (21-day cycle)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZN-A-1041 + T-Dxd 5.4 mg/kg iv. for Phase1b
Description: ZN-A-1041: twice a day (BID) via oral administration T-DXd: 5.4 mg/kg given as an intravenous infusion on the first day of each treatment cycle, once every 3 weeks (21-day cycle)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase1b
Description: ZN-A-1041: twice a day (BID) via oral administration PHESGO dose is 600 mg pertuzumab/600 mg trastuzumab/2000 unites hyaluronidase every 3 weeks for subcutaneous administrations (21-day cycle) Perjeta is 420 mg administered as an intravenous infusion Herceptin is 6 mg/kg administered as an intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase1c
Description: ZN-A-1041: twice a day (BID) via oral administration T-DM1: intravenous infusion on the first day of each treatment cycle, once every 3 weeks (21-day cycle)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZN-A-1041 + T-Dxd 5.4 mg/kg iv. for Phase1c
Description: ZN-A-1041: twice a day (BID) via oral administration T-DXd: intravenous infusion on the first day of each treatment cycle, once every 3 weeks (21-day cycle)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase1c
Description: ZN-A-1041: twice a day (BID) via oral administration PHESGO: every 3 weeks for subcutaneous administrations (21-day cycle) Perjeta: intravenous infusion Herceptin: intravenous infusion
Study: NCT01707017

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Strength training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Strength training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Strength training
Study: NCT03759938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Direct oral anticoagulant (DOAC)
Description: Any of the DOACs listed above may be used for treatment in either study arm. The DOAC will be supplied from normal hospital stock, using local hospital prescriptions.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Direct oral anticoagulant (DOAC)
Description: Any of the DOACs listed above may be used for treatment in either study arm. The DOAC will be supplied from normal hospital stock, using local hospital prescriptions.
Study: NCT03885687

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise with Music
Description: The Exercise with Music intervention is recorded exercise playlist, which provide exercise instructions tailored to patients' musical choices and exercise capacity.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: The exercise group will receive exercise brochure and will be advised to exercise at least twice daily.
Study: NCT03300583

Intervention type: BEHAVIORAL
Intervention: Focus groups
Description: Focus group discussion led by the PI and facilitated by another researcher.

Intervention type: BEHAVIORAL
Intervention: Focus groups
Description: Focus group discussion led by the PI and facilitated by another researcher.

Intervention type: BEHAVIORAL
Intervention: Semi-structured interviews
Description: 1:1 semi-structured interviews led by the PI
Study: NCT00551629

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AR51 (12, 10)
Description: vaccine formulation containing 12 mcg of PRP-T and 10 mcg of HBsAg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PR51 (3, 10)
Description: vaccine formulation containing 3 mcg of PRP-OMPC and 10 mcg of HBsAg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PR51 (6, 10)
Description: vaccine formulation containing 6 mcg of PRP-OMPC and 10 mcg of HBsAg
Study: NCT00685581

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ruminant trans fatty acid enriched diet - lowest ratio
Description: the lowest R-TFA/SFA ratio obtained from dairy cows in Winter period

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ruminant trans fatty acid enriched diet - medium ratio
Description: the medium R-TFA/SFA ratio obtained from dairy cows feeding with Winter diet supplemented with 4.1% flax seed

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ruminant trans fatty acid enriched diet - highest ratio
Description: the highest R-TFA/SFA ratio obtained from dairy cows feeding with Winter diet supplemented with 9% flax seed